2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Timothy M. Schmidt, MD, discusses the promise of bispecific antibodies in patients with multiple myeloma.
Timothy M. Schmidt, MD, an assistant professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the promise of bispecific antibodies in patients with multiple myeloma.
Bispecific antibodies are beginning to emerge as an effective treatment option for patients with multiple myeloma, according to Schmidt. These agents are capable of controlling disease and eliciting impressive response rates, Schmidt adds.
Several bispecific agents are available to choose from, although it is still not clear as which agent will emerge as the best option for this patient population, Schmidt says. More patients need to enroll on clinical trials to better understand how the use of bispecifics can be optimized, both as single agents and in combination with other BCMA-directed therapies, Schmidt concludes.